Table 10.
Effects of medical cannabis on fibromyalgia syndrome at 1, 3, and 12 months
| Prior MC | With MC | P | Prior MC | With MC | P | Prior MC | With MC | P | |
|---|---|---|---|---|---|---|---|---|---|
| 1 month, 30 patients | 3 months, 18 patients | 12 months, 12 patients | |||||||
| Widespread pain index (WPI) | |||||||||
| Median | 14.5 | 12 | <0.01 | 15 | 7 | <0.01 | 15 | 8 | >0.01 |
| IQR | 6.25 | 10.5 | 7.25 | 15.5 | 7.75 | 14.25 | |||
| Mean | 14.4 | 10.9 | 15 | 7 | 15 | 8 | |||
| ± SD | 3.9 | 6.3 | 4.2 | 7.1 | 4.8 | 7 | |||
| Severity score (SyS) | |||||||||
| Median | 11 | 9 | <0.01 | 11 | 7 | <0.01 | 10.5 | 6.5 | <0.01 |
| IQR | 1.25 | 4 | 1.5 | 4 | 2 | 6.25 | |||
| Mean | 11 | 9 | 11 | 7 | 10.5 | 6.5 | |||
| ± SD | 1.3 | 2.9 | 1.3 | 3.2 | 1.3 | 3.3 | |||
MC medical cannabis, IQR interquartile range, ± plus/minus, SD standard deviation. Fibromyalgia syndrome was measured with Widespread Pain Index (WPI) and with Severity Score (SyS). Wilcoxon signed-rank test was used to evaluate differences between time points